British National Formulary (BNF) 92 : September 2026 – March 2027

Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care. Extensive content updates in the BNF 92 edition include: New monographs for: Imvanex® [smallpox and mpox vaccines] for pre-exposure immunisation and post-exposure prophylaxis against smallpox and mpox infection Lyfnua® [gefapixant] for chronic cough MHRA advice on: Chikungunya vaccine (live) (IXCHIQ®): updates to restrictions of use following safety review GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases (advice provided in dulaglutide, liraglutide, semaglutide, and tirzepatide drug monographs) Improving information supplied with Gabapentinoids (pregabalin/gabapentin), Benzodiazepines and Z-drugs (advice in provided in gabapentin, pregabalin, all benzodiazepines, eszopiclone, zolpidem tartrate, and zopiclone drug monographs) Isotretinoin: changes to prescribing guidance and additional risk minimisation measures Mesalazine: risk of idiopathic intracranial hypertension Semaglutide (Rybelsus®): transition to new formulation and risk of medication error Semaglutide (Wegovy®, Ozempic®, and Rybelsus®): risk of non-arteritic anterior ischaemic optic neuropathy (NAION) Other significant changes include updated guidance on: 5α-reductase inhibitors (dutasteride and finasteride): update to monitoring Adrenaline/epinephrine: name change to adrenaline Antibacterials, use for prophylaxis: updated guidance for endoscopic retrograde cholangiopancreatography, transrectal prostate biopsy, and transurethral resection of prostate Cannabis extract: name change to cannabidiol with dronabinol Ceftazidime with avibactam: new indication and dose for bacteraemia and update to indication for Gram-negative infections Chronic heart failure: updated guidance on management COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign Cyclogest® pessaries [progesterone]: new indication and dose for prevention of preterm birth Diarrhoea (acute): updated guidance on the use of antibacterial drugs for acute diarrhoea Epilepsy: updated guidance on management Givinostat: new important safety information Helminth infections: updated guidance for roundworm and hookworm infections Hepatitis B vaccine: updated guidance for post-exposure prophylaxis of neonates Immunisation schedule: updated guidance for immunisation against respiratory syncytial virus Influenza: updated guidance on management Migraine: updated guidance on management Noradrenaline/norepinephrine: name change to noradrenaline Obinutuzumab: new indication and dose for lupus nephritis Penicillins and Penicillamine: harm from incorrect recording of a penicillin allergy as a penicillamine allergy [National Patient Safety Alert advice] Prednisolone: new indications and doses for adrenalin sufficiency and congenital adrenal hyperplasia Respiratory system infections, antibacterial therapy: updated guidance on community-acquired pneumonia and hospital-acquired pneumonia Semaglutide (Wegovy®): update to indications and dosing for weight management Sepsis: updated guidance on intravenous fluids and vasopressors Vaccination, general principle: updated guidance on vaccination in pregnancy Vitamins: updated guidance for management of vitamin D deficiency Vutrisiran: new indications and dose for treatment of wild-type and hereditary transthyretin amyloidosis inpatients with cardiomyopathy Zanamivir: update to indications for prophylaxis and treatment of influenza BNF is published jointly by BMJ Group and Pharmaceutical Press.